Royalty Pharma (RPRX) Net Margin Growth (3y) (2022 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) Net Margin Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -374.00 |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -44.00 |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 6,620.00 |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -13,815.00 |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 7,793.00 |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 9,934.00 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -5,319.00 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 31,387.00 |
| 10 | Incyte | 25.57 Bn | 21.04 Bn | 1.57 Bn | 1,366.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,319.00 |
| Mar 31, 2026 | -17.00 |
| Dec 31, 2025 | 16,505.00 |
| Sep 30, 2025 | 3,447.00 |
| Jun 30, 2025 | -7,572.00 |
| Mar 31, 2025 | 5,366.00 |
| Dec 31, 2024 | 4,700.00 |
| Sep 30, 2024 | 10,493.00 |
| Jun 30, 2024 | -10,919.00 |
| Mar 31, 2024 | -2,850.00 |
| Dec 31, 2023 | 5,631.00 |
| Sep 30, 2023 | -9,318.00 |
| Jun 30, 2023 | -5,254.00 |
| Mar 31, 2023 | 5,265.00 |
| Dec 31, 2022 | -42,402.00 |
| Sep 30, 2022 | -5,634.00 |
| Jun 30, 2022 | 5,266.00 |